Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era

Macdonald, Douglas C.; Nelson, Mark; Bower, Mark; Powles, Thomas; Rosa, Heitor
March 2008
World Journal of Gastroenterology;3/21/2008, Vol. 14 Issue 11, p1657
Academic Journal
The incidence of hepatocellular carcinoma (HCC) in patients with human immunodeficiency virus (HIV) is rising. HCC in HIV almost invariably occurs in the context of hepatitis C virus (HCV) or hepatitis B virus (HBV) co-infection and, on account of shared modes of transmission, this occurs in more than 33% and 10% of patients with HIV worldwide respectively. It has yet to be clearly established whether HIV directly accelerates HCC pathogenesis or whether the rising incidence is an epiphenomenon of the highly active antiretroviral therapy (HAART) era, wherein the increased longevity of patients with HIV allows long-term complications of viral hepatitis and cirrhosis to develop. Answering this question will have implications for HCC surveillance and the timing of HCV/HBV therapy, which in HIV co-infection presents unique challenges. Once HCC develops, there is growing evidence that HIV co-infection should not preclude conventional therapeutic strategies, including liver transplantation.


Related Articles

  • Increasing Incidence of Hepatocellular Carcinoma in HIV-Infected Patients in Spain. Merchante, Nicolás; Merino, Esperanza; López-Aldeguer, José; Jover, Francisco; Delgado-Fernández, Marcial; Galindo, Maria José; Ortega, Enrique; Rivero, Antonio; Mínguez, Carlos; Romero-Palacios, Alberto; Padilla, Sergio; Márquez-Solero, Manuel; Amador, Concepción; Ríos-Villegas, Maria José; Téllez, Francisco; Portilla, Joaquín; Pineda, Juan A. // Clinical Infectious Diseases;Jan2013, Vol. 56 Issue 1, p143 

    We report that the incidence of hepatocellular carcinoma (HCC) is increasing in human immunodeficiency virus (HIV)–infected patients in Spain. Thus, the incidence of HCC in HIV/hepatitis C virus–coinfected patients increased from 0.2 cases per 1000 person-years in 2000 to 2.8 cases...

  • Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Riediger, Carina; Berberat, Pascal O.; Sauer, Peter; Gotthardt, Daniel; Weiss, Karl Heinz; Mehrabi, Arianeb; Merle, Uta; Stremmel, Wolfgang; Encke, Jens // Nephrology Dialysis Transplantation;2007, Vol. 22 Issue suppl_8, pviii37 

    Chronic hepatitis B or C can cause severe liver diseases such as liver cirrhosis and hepatocellular carcinoma (HCC). Both viral infections together especially hepatitis c virus infection (HCV) are the mayor indication for liver transplantation in Western Europe and the United States. Recurrence...

  • Saquinavir exposure in HIV-infected patients with chronic viral hepatitis. Moltó, José; Llibre, Josep Maria; Ribera, Esteban; Mínguez, Carlos; del Río, Jesús Sánchez; Pedrol, Enric; Vallecillo, Gabriel; Cedeño, Samandhy; Valle, Marta; Miranda, Cristina; Negredo, Eugenia; Clotet, Bonaventura // Journal of Antimicrobial Chemotherapy (JAC);May2009, Vol. 63 Issue 5, p992 

    : Objectives The aim of this study was to assess the influence of hepatitis B virus or hepatitis C virus co-infection and the extent of liver fibrosis on saquinavir and ritonavir pharmacokinetics in HIV-infected subjects without liver function impairment. : Methods A cross-sectional,...

  • Liver Cancer Risk Up, AIDS Cancer Risk Down in US/Canadian HIV Group.  // HIV Treatment ALERTS!;Sep2012, p31 

    The article presents a research that investigates the trends of HIV-positive individuals having liver cancer in the U.S. and Canada. Researchers studied the trends of two AIDS cancers and seven non-AIDS cancer cases of individuals up to 60 years old between 1996 to 2008 and assess how the...

  • Antiretrovirals/sorafenib.  // Reactions Weekly;May2014, Vol. 1502 Issue 1, p7 

    An abstract of the article "Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients," by A. Mancuso and colleagues is presented.

  • Late Recurrence of Hepatocellular Carcinoma after Liver Transplantation. Chok, Kenneth S. H.; See Ching Chan; Tan To Cheung; Chan, Albert C. Y.; Sheung Tat Fan; Chung Mau Lo // World Journal of Surgery;Sep2011, Vol. 35 Issue 9, p2058 

    Background: Long-term survival of patients with hepatocellular carcinoma (HCC) after liver transplantation is affected mainly by recurrence of HCC. There is the opinion that the chance of recurrence after 2 years post-transplantation is remote, and therefore lifelong surveillance is not...

  • Impact of a Living Donor Liver Transplant Program for Hepatocellular Carcinoma to the Running Local Deceased Donor Liver Transplant Program. Sotiropoulos, G. C.; Malagó, M.; Molmenti, E. P.; Radtke, A.; Fouzas, I.; Beckebaum, S.; Saner, F. H.; Paul, A.; Lang, H.; Broelsch, C. E. // Digestive Diseases & Sciences;Mar2010, Vol. 55 Issue 3, p872 

    The article reports on a study examining the positive and negative consequences of a Living Donor Liver Transplantation (LDLT) program for hepatocellular carcinoma (HCC) to the running local deceased donor liver program. It was found in the study that the use of deceased donor grafts to...

  • Prevalence of Metastases in Hepatocellular Carcinoma: Risk Factors and Impact on Survival. Ming-Sing Si; Amersi, Farin; Golish, S. Raymond; Ortiz, Jorge A.; Zaky, Joseph; Finklestein, Debbie; Busuttil, Ronald W.; Imagawa, David K. // American Surgeon;Oct2003, Vol. 69 Issue 10, p879 

    The purpose of this study was to determine the prevalence and risk factors of metastases in hepatocellular carcinoma (HCC) patients and analyze the effects of different locations of metastases on survival. Retrospective analysis was performed on 347 HCC patients who received a metastatic workup...

  • Hepatocellular Carcinoma Screening Practices in the Department of Veterans Affairs: Findings from a National Facility Survey. El-Serag, Hashem; Alsarraj, Abeer; Richardson, Peter; Davila, Jessica; Kramer, Jennifer; Durfee, Janet; Kanwal, Fasiha // Digestive Diseases & Sciences;Nov2013, Vol. 58 Issue 11, p3117 

    Background: Previous studies suggest low rates of hepatocellular carcinoma (HCC) screening in clinical practice. There is little information on the provider- and healthcare-facility-related factors that explain the use of HCC screening. Aims: We used data from the 2007 Survey to Assess Hepatitis...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics